• 1
    Smith HO,Tiffany MF,Qualls CR,Key CR. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States—a 24-year population-based study. Gynecol Oncol 2000; 78: 97105.
  • 2
    Dijck vanJAAM,CoeberghJWW,SieslingS,VisserO, eds. Trends of Cancer in the Netherlands 1989–1998. Utrecht: Vereniging van Integrale Kankercentra, 2002.
  • 3
    Chen RJ,Lin YH,Chen CA,Huang SC,Chow SN,Hsieh CY. Influence of histologic type and age on survival rates for invasive cervical carcinoma in Taiwan. Gynecol Oncol 1999; 73: 18490.
  • 4
    Eifel PJ,Burke TW,Morris M,Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol 1995; 59: 3844.
  • 5
    Hopkins MP,Morley GW. A comparison of adenocarcinoma and squamous cell carcinoma of the cervix. Obstet Gynecol 1991; 77: 91217.
  • 6
    Nakanishi T,Ishikawa H,Suzuki Y,Inoue T,Nakamura S,Kuzuya K. A comparison of prognoses of pathologic stage Ib adenocarcinoma and squamous cell carcinoma of the uterine cervix. Gynecol Oncol 2000; 79: 28993.
  • 7
    Grisaru D,Covens A,Chapman B,Shaw P,Colgan T,Murphy J,DePetrillo D,Lickrish G,Laframboise S,Rosen B. Does histology influence prognosis in patients with early-stage cervical carcinoma? Cancer 2001; 92: 29993004.
  • 8
    Ireland D,Hardiman P,Monaghan JM. Adenocarcinoma of the uterine cervix: a study of 73 cases. Obstet Gynecol 1985; 65: 825.
  • 9
    Ishikawa H,Nakanishi T,Inoue T,Kuzuya K. Prognostic factors of adenocarcinoma of the uterine cervix. Gynecol Oncol 1999; 73: 426.
  • 10
    Leminen A,Paavonen J,Forss M,Wahlstrom T,Vesterinen E. Adenocarcinoma of the uterine cervix. Cancer 1990; 65: 539.
  • 11
    Clark GM,McGuire WL,Hubay CA,Pearson OH,Marshall JS. Progesterone receptors as a prognostic factor in Stage II breast cancer. N Engl J Med 1983; 309: 13437.
  • 12
    Fukuda K,Mori M,Uchiyama M,Iwai K,Iwasaka T,Sugimori H. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma. Gynecol Oncol 1998; 69: 2205.
  • 13
    Allred DC,Clark GM,Elledge R,Fuqua SA,Brown RW,Chamness GC,Osborne CK,McGuire WL. Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 1993; 85: 2006.
  • 14
    Zellars RC,Hilsenbeck SG,Clark GM,Allred DC,Herman TS,Chamness GC,Elledge RM. Prognostic value of p53 for local failure in mastectomy-treated breast cancer patients. J Clin Oncol 2000; 18: 190613.
  • 15
    Geisler JP,Geisler HE,Miller GA,Wiemann MC,Zhou Z,Crabtree W. p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months. Gynecol Oncol 2000; 77: 27882.
  • 16
    Wootipoom V,Lekhyananda N,Phungrassami T,Boonyaphiphat P,Thongsuksai P. Prognostic significance of Bax, Bcl-2, and p53 expressions in cervical squamous cell carcinoma treated by radiotherapy. Gynecol Oncol 2004; 94: 63642.
  • 17
    Graflund M,Sorbe B,Hussein A,Bryne M,Karlsson M. The prognostic value of histopathologic grading parameters and microvessel density in patients with early squamous cell carcinoma of the uterine cervix. Int J Gynecol Cancer 2002; 12: 3241.
  • 18
    Geisler JP,Geisler HE,Wiemann MC,Zhou Z,Miller GA,Crabtree W. MIB-1: a predictor of survival in patients with ovarian carcinoma. Int J Gynecol Cancer 1998; 8: 3926.
  • 19
    Dimitrakakis C,Kymionis G,Diakomanolis E,Papaspyrou I,Rodolakis A,Arzimanoglou I,Leandros E,Michalas S. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions. Gynecol Oncol 2000; 77: 12936.
  • 20
    Tavassoli FA,Devilee P. Pathology and genetics tumours of the breast and female organs. In: TavassoliFA,DevileeP, eds. World Health Organisation classification of tumours. Lyon: IARC Press, 2003. 2727.
  • 21
    Kurman RJ,Norris HJ,Wilkinson E. Tumors of the cervix, vagina and vulva. In: RosaiJ, ed. Atlas of tumor pathology. Washinton, DC: Armed Forces Institute of Pathology, 1992. p 87.
  • 22
    van der Zee J,Gonzalez GD. The Dutch Deep Hyperthermia Trial: results in cervical cancer. Int J Hyperthermia 2002; 18: 112.
  • 23
    Cambruzzi E,Zettler CG,Alexandre CO. Expression of Ki-67 and squamous intraepithelial lesions are related with HPV in endocervical adenocarcinoma. Pathol Oncol Res 2005; 11: 11420.
  • 24
    Tangjitgamol S,Ramirez PT,Sun CC,See HT,Jhingran A,Kavanagh JJ,Deavers MT. Expression of HER-2/neu, epidermal growth factor receptor, vascular endothelial growth factor, cyclooxygenase-2, estrogen receptor, and progesterone receptor in small cell and large cell neuroendocrine carcinoma of the uterine cervix: a clinicopathologic and prognostic study. Int J Gynecol Cancer 2005; 15: 64656.
  • 25
    Nofech-Mozes S,Rasty G,Ismiil N,Covens A,Khalifa MA. Immunohistochemical characterization of endocervical papillary serous carcinoma. Int J Gynecol Cancer 2006; 16 ( Suppl 1): 28692.
  • 26
    Alkushi A,Irving J,Hsu F,Dupuis B,Liu CL,Rijn M,Gilks CB. Immunoprofile of cervical and endometrial adenocarcinomas using a tissue microarray. Virchows Arch 2003; 442: 2717.
  • 27
    Alkushi A,Lim P,Coldman A,Huntsman D,Miller D,Gilks CB. Interpretation of p53 immunoreactivity in endometrial carcinoma: establishing a clinically relevant cut-off level. Int J Gynecol Pathol 2004; 23: 12937.
  • 28
    Van de Putte G,Kristensen GB,Lie AK,Baekelandt M,Holm R. Cyclins and proliferation markers in early squamous cervical carcinoma. Gynecol Oncol 2004; 92: 406.
  • 29
    Chang J,Clark GM,Allred DC,Mohsin S,Chamness G,Elledge RM. Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer 2003; 97: 54553.
  • 30
    Steiner E,Eicher O,Sagemuller J,Schmidt M,Pilch H,Tanner B,Hengstler JG,Hofmann M,Knapstein PG. Multivariate independent prognostic factors in endometrial carcinoma: a clinicopathologic study in 181 patients: 10 years experience at the Department of Obstetrics and Gynecology of the Mainz University. Int J Gynecol Cancer 2003; 13: 197203.
  • 31
    Staebler A,Sherman ME,Zaino RJ,Ronnett BM. Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas. Am J Surg Pathol 2002; 26: 9981006.
  • 32
    Harding M,McIntosh J,Paul J,Symonds RP,Reed N,Habeshaw T,Stewart M,Leake RE. Oestrogen and progesterone receptors in carcinoma of the cervix. Clin Oncol (R Coll Radiol) 1990; 2: 31317.
  • 33
    Fujiwara H,Tortolero-Luna G,Mitchell MF,Koulos JP,Wright TC,Jr. Adenocarcinoma of the cervix. Expression and clinical significance of estrogen and progesterone receptors. Cancer 1997; 79: 50512.
  • 34
    Suzuki Y,Nakano T,Arai T,Morita S,Tsujii H,Oka K. Progesterone receptor is a favorable prognostic factor of radiation therapy for adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 2000; 47: 122934.
  • 35
    Masood S,Rhatigan RM,Wilkinson EW,Barwick KW,Wilson WJ. Expression and prognostic significance of estrogen and progesterone receptors in adenocarcinoma of the uterine cervix. An immunocytochemical study. Cancer 1993; 72: 51118.
  • 36
    Ghandour FA,Attanoos R,Nahar K,Gee JW,Bigrigg A,Ismail SM. Immunocytochemical localization of oestrogen and progesterone receptors in primary adenocarcinoma of the cervix. Histopathology 1994; 24: 4955.
  • 37
    Geisinger KR,Homesley HD,Morgan TM,Kute TE,Marshall RB. Endometrial adenocarcinoma. A multiparameter clinicopathologic analysis including the DNA profile and the sex steroid hormone receptors. Cancer 1986; 58: 151825.
  • 38
    McCluggage WG. Immunohistochemical and functional biomarkers of value in female genital tract lesions. Int J Gynecol Pathol 2006; 25: 10120.
  • 39
    O'Neill CJ,Deavers MT,Malpica A,Foster H,McCluggage WG. An immunohistochemical comparison between low-grade and high-grade ovarian serous carcinomas: significantly higher expression of p53, MIB1, BCL2, HER-2/neu, and C-KIT in high-grade neoplasms. Am J Surg Pathol 2005; 29: 103441.
  • 40
    Hunt CR,Hale RJ,Buckley CH,Hunt J. p53 expression in carcinoma of the cervix. J Clin Pathol 1996; 49: 9714.
  • 41
    Harmsel ter B,Muyden van R,Smedts F,Hermans J,Kuijpers J,Raikhlin N,Petrov S,Lebedev A,Ramaekers F,Trimbos B. The significance of cell type and tumor growth markers in the prognosis of unscreened cervical cancer patients. Int J Gynecol Cancer 1998; 8: 33644.
  • 42
    Graflund M,Sorbe B,Karlsson M. Immunohistochemical expression of p53, bcl-2, and p21(WAF1/CIP1) in early cervical carcinoma: correlation with clinical outcome. Int J Gynecol Cancer 2002; 12: 2908.
  • 43
    Lee JS,Kim HS,Jung JJ,Lee MC,Park CS. Expression of vascular endothelial growth factor in adenocarcinomas of the uterine cervix and its relation to angiogenesis and p53 and c-erbB-2 protein expression. Gynecol Oncol 2002; 85: 46975.
  • 44
    Saito T,Takehara M,Tanaka R,Lee R,Horie M,Wataba K,Ito E,Kudo R. Correlation between responsiveness of neoadjuvant chemotherapy and apoptosis-associated proteins for cervical adenocarcinoma. Gynecol Oncol 2004; 92: 28492.
  • 45
    Crawford RA,Caldwell C,Iles RK,Lowe D,Shepherd JH,Chard T. Prognostic significance of the bcl-2 apoptotic family of proteins in primary and recurrent cervical cancer. Br J Cancer 1998; 78: 21014.
  • 46
    Uchiyama M,Iwasaka T,Matsuo N,Hachisuga T,Mori M,Sugimori H. Correlation between human papillomavirus positivity and p53 gene overexpression in adenocarcinoma of the uterine cervix. Gynecol Oncol 1997; 65: 239.
  • 47
    Huang LW,Chou YY,Chao SL,Chen TJ,Lee TT. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome. Gynecol Oncol 2001; 83: 34854.
  • 48
    Suzuki Y,Nakano T,Kato S,Ohno T,Tsujii H,Oka K. Immunohistochemical study of cell cycle-associated proteins in adenocarcinoma of the uterine cervix treated with radiotherapy alone: P53 status has a strong impact on prognosis. Int J Radiat Oncol Biol Phys 2004; 60: 2316.
  • 49
    Wintzer HO,Zipfel I,Schulte-Monting J,Hellerich U,von Kleist S. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991; 67: 4218.
  • 50
    Garzetti GG,Ciavattini A,Lucarini G,Goteri G,De Nictolis M,Muzzioli M,Fabris N,Romanini C,Biagini G. MIB 1 immunostaining in stage I squamous cervical carcinoma: relationship with natural killer cell activity. Gynecol Oncol 1995; 58: 2833.
  • 51
    Morimura Y,Yanagida K,Hashimoto T,Takano Y,Watanabe F,Yamada H,Sato A. Evaluation of immunostaining for MIB1 and nm23 products in uterine cervical adenocarcinoma. Tohoku J Exp Med 1998; 185: 18597.
  • 52
    Nakano T,Oka K. Differential values of Ki-67 index and mitotic index of proliferating cell population. An assessment of cell cycle and prognosis in radiation therapy for cervical cancer. Cancer 1993; 72: 24018.
  • 53
    McCluggage WG,McBride H,Maxwell P,Bharuch H. Immunohistochemical detection of p53 and bcl-2 proteins in neoplastic and non-neoplastic endocervical glandular lesions. Int J Gynecol Pathol 1997; 16: 227.
  • 54
    Pillai MR,Jayaprakash PG,Nair MK. bcl-2 immunoreactivity but not p53 accumulation associated with tumour response to radiotherapy in cervical carcinoma. J Cancer Res Clin Oncol 1999; 125: 5560.